Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.59 |
| ▸ | PDE4A | P27815 | 10/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537211 | 1.00 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL8288776 | 0.93 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL2465157 | 0.93 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL8279948 | 0.92 | PDE4B (0.50) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537220 | 0.91 | TP53 (0.50) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1143358 | 0.91 | PDE4B (0.49) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1582796 | 0.91 | TP53 (0.50) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL694628 | 0.91 | PDE4B (0.49) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537241 | 0.91 | PDE4B (0.49) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL8279946 | 0.89 | TP53 (0.47) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1698334-B1 | Pharmaceutically active isoindoline derivatives | CELGENE CORP (US) | 2011-04-20 | — | — | EP | claimed |
| WO-2017070291-A1 | PDE4 MODULATORS FOR TREATING AND PREVENTING IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS) | CELGENE CORPORATION (US) | 2017-04-27 | — | — | WO | disclosed |
| US-9138427-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-1228071-B8 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-1228071-A4 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1228071-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001034606-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |